Moomoo AI 已提取核心信息
On February 2, 2024, Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, reported a significant stake in Invivyd, Inc. According to the Schedule 13G filed with the SEC, the group collectively owns 9,000,000 shares of Invivyd's common stock, which represents 7.56% of the company's class of securities. The filing, made under Rule 13d-1(c), indicates that the shares are held with shared voting and dispositive power. The principal business offices for Deep Track Capital and David Kroin are located in Greenwich, CT, while Deep Track Biotechnology Master Fund is based in the Cayman Islands. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Invivyd, Inc., and there...Show More
On February 2, 2024, Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, reported a significant stake in Invivyd, Inc. According to the Schedule 13G filed with the SEC, the group collectively owns 9,000,000 shares of Invivyd's common stock, which represents 7.56% of the company's class of securities. The filing, made under Rule 13d-1(c), indicates that the shares are held with shared voting and dispositive power. The principal business offices for Deep Track Capital and David Kroin are located in Greenwich, CT, while Deep Track Biotechnology Master Fund is based in the Cayman Islands. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Invivyd, Inc., and there is no intention to participate in any transaction with such a purpose or effect. The statement was duly signed by David Kroin, who serves as the Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, and as a Director for Deep Track Biotechnology Master Fund, Ltd.
2024年2月2日，Deep Track Capital, LP以及Deep Track Biotechnology Master Fund, Ltd.和David Kroin报告了Invivyd, Inc.的大量股份。根据向美国证券交易委员会提交的附表13G，该集团共拥有900万股普通股，占该公司证券类别的7.56％。根据第13d-1（c）条提交的文件表明，股份持有的是共同的投票权和处置权。Deep Track Capital和David Kroin的主要业务办公室位于康涅狄格州格林威治，而Deep Track Biotechnology主基金则设在开曼群岛。该文件称，收购这些股份不是为了改...展开全部
2024年2月2日，Deep Track Capital, LP以及Deep Track Biotechnology Master Fund, Ltd.和David Kroin报告了Invivyd, Inc.的大量股份。根据向美国证券交易委员会提交的附表13G，该集团共拥有900万股普通股，占该公司证券类别的7.56％。根据第13d-1（c）条提交的文件表明，股份持有的是共同的投票权和处置权。Deep Track Capital和David Kroin的主要业务办公室位于康涅狄格州格林威治，而Deep Track Biotechnology主基金则设在开曼群岛。该文件称，收购这些股份不是为了改变或影响Invivyd, Inc. 的控制权，也无意参与任何具有此类目的或效果的交易。该声明由戴维·克罗因正式签署，他是Deep Track Capital, LP投资顾问普通合伙人的管理成员和Deep Track Biotechnology Master Fund, Ltd的董事。
有用
没用